Centogene Extends Strategic Partnership With Takeda

Centogene N.V. recently announced it has extended its partnership with Takeda to diagnose patients with Lysosomal Storage Disorders (LSDs). Under the renewed 1-year partnership agreement, Centogene will continue to provide Takeda with access to diagnostic testing for patients around the world. The aim of the commercial fee-for-service agreement is to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.

“We are excited to extend our partnership with Takeda to accelerate diagnosis and increase access to life-saving therapeutics for patients globally,” said Ian Rentsch, Centogene Chief Commercial Officer and General Manager – Pharma. “Leveraging our targeted diagnostic portfolio, network of over 30,000 active physicians, and the Centogene Biodatabank driving novel insights, we are uniquely positioned to deliver substantial value to our pharma partners throughout every stage of the development pipeline. This collaboration continues to play a vital role in the expansion of Takeda’s world-class enzyme replacement treatments and most importantly, brings life-changing answers to underserved patient communities.”

A key asset to the partnership is the Centogene Biodatabank, which currently contains approximately 700,000 patients representing over 120 highly diverse countries, more than 70% of whom are of non-European descent, including a large share of pediatric cases. By integrating multiomic and multi-ethnic data, the Centogene Biodatabank captures a holistic view to enable the most accurate diagnosis and guide clinical actions.

In January 2015, Centogene originally entered into an agreement with Shire Pharmaceuticals, which was acquired in 2019 by Takeda, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from rare genetic diseases. Last year, the contract was extended until March 2023.

Centogene’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the Centogene Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Since our founding in 2006, Centogene has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our Centogene Biodatabank, with nearly 700,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the Centogene Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.

By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target & drug screening, clinical development, market access and expansion, as well as offering Centogene Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases. For more nformation, visit www.centogene.com.